Published in Neurobiol Dis on May 07, 2010
Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology (2010) 2.31
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol (2011) 1.64
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain (2011) 1.55
Is there room for non-dopaminergic treatment in Parkinson disease? J Neural Transm (Vienna) (2012) 1.40
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology (2010) 1.30
α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev (2011) 1.29
Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis (2013) 1.20
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm (Vienna) (2011) 1.12
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest (2012) 0.98
Modeling Parkinson's disease in primates: The MPTP model. Cold Spring Harb Perspect Med (2012) 0.94
Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity. PLoS One (2010) 0.93
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications. Front Neurol (2014) 0.92
Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias. Br J Pharmacol (2015) 0.88
Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function. Neurobiol Dis (2012) 0.88
Behavioural profiles in captive-bred cynomolgus macaques: towards monkey models of mental disorders? PLoS One (2013) 0.88
α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology (2013) 0.87
Metabotropic glutamate receptor-mediated signaling in neuroglia. Wiley Interdiscip Rev Membr Transp Signal (2012) 0.84
Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats. PLoS One (2010) 0.84
Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation. Mol Pharmacol (2015) 0.83
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? BMC Med (2013) 0.82
Fenobam sulfate inhibits cocaine-taking and cocaine-seeking behavior in rats: implications for addiction treatment in humans. Psychopharmacology (Berl) (2013) 0.81
Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease. Neurosci Lett (2010) 0.80
Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Neuropharmacology (2015) 0.80
Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Neurotherapeutics (2014) 0.80
Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates. Front Neurol (2014) 0.79
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease. Proc Natl Acad Sci U S A (2015) 0.78
p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism. Proc Natl Acad Sci U S A (2016) 0.78
Therapeutic potential of targeting glutamate receptors in Parkinson's disease. J Neural Transm (Vienna) (2014) 0.78
Striatal glutamate release in L-DOPA-induced dyskinetic animals. PLoS One (2013) 0.78
VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy. J Pharmacol Exp Ther (2015) 0.77
mGluR5 Positive and Negative Allosteric Modulators Differentially Affect Dendritic Spine Density and Morphology in the Prefrontal Cortex. CNS Neurol Disord Drug Targets (2015) 0.77
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia. J Neural Transm (Vienna) (2010) 0.76
mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias. Curr Neuropharmacol (2016) 0.75
Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders. Neuron (2017) 0.75
Interaction between the mGlu receptors 5 antagonist, MPEP, and amphetamine on memory and motor functions in mice. Psychopharmacology (Berl) (2012) 0.75
Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature (2003) 14.49
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med (2013) 8.76
A post-transcriptional regulatory switch in polypyrimidine tract-binding proteins reprograms alternative splicing in developing neurons. Genes Dev (2007) 5.83
Comparing genomic expression patterns across species identifies shared transcriptional profile in aging. Nat Genet (2004) 4.77
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Evolution of alternative transcriptional circuits with identical logic. Nature (2006) 3.58
The evolution of combinatorial gene regulation in fungi. PLoS Biol (2008) 3.53
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci (2003) 3.25
Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet (2007) 3.24
The draft genome of a diploid cotton Gossypium raimondii. Nat Genet (2012) 3.18
Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev (2007) 2.96
Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol (2008) 2.68
A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol (2012) 2.54
Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology (2007) 2.39
Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol (2014) 2.33
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol (2009) 2.28
Evolution of eukaryotic transcription circuits. Science (2008) 2.24
Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov (2006) 2.23
Dynamic XML-based exchange of relational data: application to the Human Brain Project. AMIA Annu Symp Proc (2003) 2.16
Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A (2012) 2.16
De novo identification and biophysical characterization of transcription-factor binding sites with microfluidic affinity analysis. Nat Biotechnol (2010) 2.05
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell (2012) 2.04
NaBC1 is a ubiquitous electrogenic Na+ -coupled borate transporter essential for cellular boron homeostasis and cell growth and proliferation. Mol Cell (2004) 2.02
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci (2002) 2.01
Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J Lipid Res (2007) 1.99
Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem (2001) 1.97
Genome-wide diversity and selective pressure in the human rhinovirus. Virol J (2007) 1.94
Diabetes and poor outcomes within 6 months after acute ischemic stroke: the China National Stroke Registry. Stroke (2011) 1.91
The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke (2011) 1.90
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
Dynamics and design principles of a basic regulatory architecture controlling metabolic pathways. PLoS Biol (2008) 1.86
Inference of combinatorial regulation in yeast transcriptional networks: a case study of sporulation. Proc Natl Acad Sci U S A (2005) 1.86
Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences. Cell (2012) 1.81
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol (2010) 1.80
Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines. Bioorg Med Chem Lett (2008) 1.80
Systematic identification of cis-regulatory sequences active in mouse and human embryonic stem cells. PLoS Genet (2007) 1.77
Gcn4p and novel upstream activating sequences regulate targets of the unfolded protein response. PLoS Biol (2004) 1.73
Epidemiological investigations of human rabies in China. BMC Infect Dis (2009) 1.72
Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J Neurosci (2007) 1.71
A systematic approach to reconstructing transcription networks in Saccharomycescerevisiae. Proc Natl Acad Sci U S A (2002) 1.70
Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp Neurol (2009) 1.70
Functional bias and spatial organization of genes in mutational hot and cold regions in the human genome. PLoS Biol (2004) 1.67
A radically configurable six-state compound. Science (2013) 1.67
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry (2007) 1.65
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol (2005) 1.65
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol (2009) 1.61
Directed evolution of ionizing radiation resistance in Escherichia coli. J Bacteriol (2009) 1.60
Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proc Natl Acad Sci U S A (2014) 1.59
Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in china who had severe fever with thrombocytopenia syndrome. Clin Infect Dis (2013) 1.58
Functional specificity of shuttling hnRNPs revealed by genome-wide analysis of their RNA binding profiles. RNA (2005) 1.58
Gain-of-function mutation in TRPML3 causes the mouse Varitint-Waddler phenotype. J Biol Chem (2007) 1.56
Variability of myocardial ischemic responses to mental versus exercise or adenosine stress in patients with coronary artery disease. J Nucl Cardiol (2008) 1.55
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis (2002) 1.54
Mutations in the fatty acid transport protein 4 gene cause the ichthyosis prematurity syndrome. Am J Hum Genet (2009) 1.53
Circulation of Coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009-2011. PLoS One (2012) 1.52
Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model. Mov Disord (2012) 1.51
Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology (2009) 1.50
Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol (2013) 1.49
Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl (2007) 1.49
A novel mode of TRPML3 regulation by extracytosolic pH absent in the varitint-waddler phenotype. EMBO J (2008) 1.47
Complete genome sequence of the nitrogen-fixing and rhizosphere-associated bacterium Pseudomonas stutzeri strain DSM4166. J Bacteriol (2011) 1.46
Association of TLR4 gene non-missense single nucleotide polymorphisms with rheumatoid arthritis in Chinese Han population. Rheumatol Int (2012) 1.45
Mitochondrial network size scaling in budding yeast. Science (2012) 1.44
Genome-wide regulatory complexity in yeast promoters: separation of functionally conserved and neutral sequence. Genome Res (2005) 1.44
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor. J Neurosci (2012) 1.43
Mental stress-induced myocardial ischemia in coronary artery disease patients with left ventricular dysfunction. J Nucl Cardiol (2007) 1.43
Repetitive oocyte donation does not decrease serum anti-Müllerian hormone levels. Fertil Steril (2009) 1.42
Coordinated reset has sustained aftereffects in Parkinsonian monkeys. Ann Neurol (2012) 1.42
A ferroelectric oxide made directly on silicon. Science (2009) 1.41
Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey. Clin Rheumatol (2014) 1.41
Perioperative Management of Patients Infected with the Novel Coronavirus: Recommendation from the Joint Task Force of the Chinese Society of Anesthesiology and the Chinese Association of Anesthesiologists. Anesthesiology (1) 1.40
Regulation of cellular plasticity in Drosophila imaginal disc cells by the Polycomb group, trithorax group and lama genes. Development (2005) 1.37
Deletion of TRPC3 in mice reduces store-operated Ca2+ influx and the severity of acute pancreatitis. Gastroenterology (2009) 1.37
Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke (2011) 1.37
The role of surface charge on the uptake and biocompatibility of hydroxyapatite nanoparticles with osteoblast cells. Nanotechnology (2011) 1.35
RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J Neurosci (2007) 1.35
Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology (2005) 1.34
A comparison of the tube forming potentials of early and late endothelial progenitor cells. Exp Cell Res (2007) 1.32
Transient receptor potential mucolipin 1 (TRPML1) and two-pore channels are functionally independent organellar ion channels. J Biol Chem (2011) 1.32
Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci (2004) 1.30
The unfolded protein response in fission yeast modulates stability of select mRNAs to maintain protein homeostasis. Elife (2012) 1.29
The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol (2007) 1.29
Sherlock: detecting gene-disease associations by matching patterns of expression QTL and GWAS. Am J Hum Genet (2013) 1.29
High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. Eur J Cancer (2013) 1.29
L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem (2009) 1.28
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci (2006) 1.28
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res (2007) 1.28
miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS Lett (2012) 1.27
Lysosomal impairment in Parkinson's disease. Mov Disord (2013) 1.27
Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J Clin Invest (2011) 1.27
A systematic approach to identify functional motifs within vertebrate developmental enhancers. Dev Biol (2009) 1.26
Retinopathy online challenge: automatic detection of microaneurysms in digital color fundus photographs. IEEE Trans Med Imaging (2009) 1.26
Shaping of motor responses by incentive values through the basal ganglia. J Neurosci (2007) 1.24